Progress of osteoporosis: stratification of fracture risk
https://doi.org/10.14341/osteo9620
Abstract
Background: There are two approaches to identify candidates for the prescription of osteoporosis treatment: identification of patients with low bone mineral density using DEXA of the axial skeleton and calculation of the 10-year probability of major osteoporotic fractures using FRAX®.
Aims: to assess the diagnostic accuracy of different FRAX® thresholds in the Russian population.
Materials and methods: the value of individual 10-year probability of osteoporotic fracture by FRAX® at the time of inclusion in the study was retrospectively estimated in 224 postmenopausal women, whom the major osteoporotic fractures were recorded over 10 years of prospective observation. The diagnostic accuracy of different thresholds were compared: "European" and Russian age-dependent thresholds, fixed 20% threshold, the average FRAX® of patients who had a major osteoporotic fracture during follow-up (16%), FRAX® value corresponding to the "cut-off point" (12,5%).
Results: The Russian FRAX model showed the acceptable diagnostic accuracy of the method (AUC=0.665±0.036; 95% CI 0.595; 0.736). The "European" threshold of therapeutic intervention demonstrated 72% sensitivity and 38% specificity, 20% threshold – 27% and 87%, the Russian threshold – 41% and 77%, 12.5% threshold – 68% and 58%, 16% threshold – 57% and 73%, respectively. The diagnostic precision of the specified thresholds was 54%, 58%, 60%, 63% and 65%, respectively.
Conclusions: the Russian age-dependent threshold remains the optimal way to decide whether to initiate anti-osteoporotic therapy based on an assessment of the 10-year probability of fracture by the Russian model for FRAX®.
About the Authors
Oksana A. NikitinskayaResearch Institute of Rheumatogy named after V.A. Nasonova
Russian Federation
Senior Researcher, Osteoporosis laboratory
Natalya V. Toroptsova
Research Institute of Rheumatogy named after V.A. Nasonova
Russian Federation
MD, PhD, head of osteoporosis laboratory
References
1. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Проблемы Эндокринологии. - 2017. - Т. 63. - №6. - C. 392-426. [Melnichenko GA, Belaya ZE, Rozhinskaya LY, et al. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2018;63(6):392-426. (In Russ).] doi: 10.14341/probl2017636392-426.
2. Kanis JA, Johnell O, Oden A, et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 2008;19(4):385-397. doi: 10.1007/s00198-007-0543-5.
3. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos. Int. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.
4. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can. Med. Assoc. J. 2010;182(17):1864-1873. doi: 10.1503/cmaj.100771.
5. Ip I, Cheung SK, Cheung TC, et al. OSHK Task Group for Formulation of 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong. Osteoporosis Society of Hong Kong The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J. 2013;19(Suppl 2):1–40.
6. Orimo H, Nakamura T, Hosoi T, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Archives of Osteoporosis. 2012;7(1-2):3-20. doi: 10.1007/s11657-012-0109-9.
7. Johansson H, Kanis JA, Ljunggren O, et al. FRAX-model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines. Lakartidningen. 2011;108(7):336-339.
8. Goncalves MJ, Rodrigues AM, Canhao H, Fonseca JE. Osteoporosis: from bone biology to individual treatment decision. Acta Med. Port. 2013;26(4):445-455.
9. Zhang Z, Ou Y, Sheng Z, Liao E. How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine. 2013;45(2):195-197. doi: 10.1007/s12020-013-0076-y.
10. Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX. Archives of Osteoporosis. 2016;11(1). doi: 10.1007/s11657-016-0278-z.
11. Chakhtoura M, Baddoura R, El-Hajj Fuleihan G. Lebanese FRAX-based osteoporosis guidelines [Internet]. Beirut. 2013. [cited 2018 Apr 3]. Available from: http://www.osteos.org.lb/admin/uploads/Full%20document.pdf.
12. Лесняк О.М. Клинические рекомендации по профилактике и ведению больных с остеопорозом.- Ярославль.: ИПК «Литера», 2013 [Lesnyak OM. Klinicheskie rekomendatsii po profilaktike i vedeniyu bol'nykh s osteoporozom. Yaroslavl: IPK «Litera»; 2013. (In Russ).]
13. Никитинская О.А., Торопцова Н.В., Демин Н.В. Факторы риска и минеральная плотность кости в прогнозировании риска перелома у женщин в постменопаузе. // Современная ревматология. - 2016. – Т. 10. - №3. - С. 23-28. [Nikitinskaya OA, Toroptsova NV, Demin NV. Risk factors and bone mineral density in predicting the risk of fracture in postmenopausal women. Modern Rheumatology Journal. 2016;10(3):23-28. (In Russ).] doi: 10.14412/1996-7012-2016-3-23-28.
14. Borgström F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? Osteoporos. Int. 2006;17(10):1459-1471. doi: 10.1007/s00198-006-0107-0.
15. Tosteson ANA, Melton LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos. Int. 2008;19(4):437-447. doi: 10.1007/s00198-007-0550-6.
16. Lippuner K, Johansson H, Borgström F, et al. Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos. Int. 2012;23(11):2579-2589. doi: 10.1007/s00198-011-1869-6.
17. Dawson-Hughes B. A Revised Clinician’s Guide to the Prevention and Treatment of Osteoporosis. J. Clin. Endocr. Metab. 2008;93(7):2463-2465. doi: 10.1210/jc.2008-0926.
18. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515-1526. doi: 10.1002/acr.20295.
19. Никитинская О.А., Торопцова Н.В. Оценка 10-летней вероятности остеопоротических переломов с помощью российской модели FRAX в популяционных выборках 5 регионов России. // Медицинский совет. – 2017. - №1S. - C. 103-107. [Nikitinskaya OA, Toroptsova NV. Ocenka 10-letnej veroyatnosti osteoporoticheskix perelomov s pomoshh`yu rossijskoj modeli FRAX v populyacionny`x vy`borkax 5 regionov Rossii. Medicinskij sovet. 2017;(1S):103-107. (In Russ).] doi: 10/21518/2079-701X-2017-0-103-107.
Supplementary files
|
|
1. Fig. 1. ROC-curve of the Russian model FRAX, AUC = 0.665 ± 0.036 (95% CI 0.595, 0.736). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(214KB)
|
Indexing metadata ▾ | |
Review
For citations:
Nikitinskaya O.A., Toroptsova N.V. Progress of osteoporosis: stratification of fracture risk. Osteoporosis and Bone Diseases. 2018;21(1):4-9. (In Russ.) https://doi.org/10.14341/osteo9620
Views:
2248
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
